New ultrasound could spot heart trouble before It's too late for chemo patients
NCT ID NCT01212926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a special heart ultrasound (2D strain imaging) can detect early signs of heart damage caused by anthracycline chemotherapy in 100 leukemia patients. The goal is to catch problems sooner, so doctors can adjust treatment and reduce the risk of permanent heart damage. Researchers measured heart function at several points over a year to see if the technique works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Echographic analysis of myocardial deformation in 2D strain (a special heart ultrasound technique)
What this could lead to
If this works, doctors could detect heart damage from chemotherapy earlier, allowing them to adjust treatment and potentially improve survival for leukemia patients.
What could go wrong
This is a small, completed study with 100 participants, so results may not apply to everyone. The technique is still experimental and not yet standard practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Service de Cardiologie et Maladies Vasculaires, Hopital du Haut Lévêque
Pessac, 33604, France